Sumitomo Dainippon Pharma Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sumitomo Dainippon Pharma Co., Ltd.
Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications.
Korea's SK Group expands its biopharma business via a sizable investment in Roivant's protein degradation platform, through which the partners aim to progress candidates in cancer, immunology and neurology, with the first entering the clinic next year.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
- Other Names / Subsidiaries
- Adagio Pharmaceuticals Ltd.
- Altavant Sciences
- Boston Biomedical, Inc.
- Boston Biomedical Pharma, Inc.
- Cannasat Therapeutics Inc.
- Cynapsus Therapeutics, Inc.
- Dainippon Sumitomo Pharma Co., Ltd.
- Dainippon Sumitomo Pharma Europe Ltd.
- DS Pharma Promo Co., Ltd,
- Elevation Pharmaceuticals, Inc.
- Enzyvant Therapeutics, Inc.
- Enzyvant Sciences, Ltd.
- Myovant Sciences Ltd
- Myovant Sciences GmbH
- Myovant Sciences, Inc.
- Oryx Pharmaceuticals Inc.
- SB Bioscience Co., Ltd.
- Spirovant Sciences
- Sumitomo Chemical Co., Ltd.
- Sumitomo Dainippon Pharma America, Inc. (formerly Dainippon Sumitomo Pharma America Holdings, Inc.)
- Sumitomo Dainippon Pharma Oncology, Inc.
- Sumitomo Pharmaceuticals America
- Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
- Sumitovant Biopharma
- Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.)
- Sunovion Pharmaceuticals Europe Ltd.
- Sunovion Respiratory Development Inc.
- Tolero Pharmaceuticals, Inc.
- Urovant Sciences, Inc.
- Sumitomo Pharmaceuticals Taiwan Co., Ltd.